Vaccination

BioNTech/Pfizer say vaccine can stand warmer temperatures

Germany's BioNTech and its US partner Pfizer on Friday said tests have shown that their coronavirus vaccine can stand warmer temperatures than initially thought, potentially simplifying the jab's complex cold-chain logistics.

Diseases, Conditions, Syndromes

Pfizer/BioNTech first dose 85% effective after 2-4 weeks: study

The first dose of the Pfizer/BioNTech vaccination is 85 percent effective against coronavirus infection between two and four weeks after inoculation, according to a study published in the Lancet medical journal.

Diseases, Conditions, Syndromes

Israeli study shows Pfizer vaccine 94 percent effective

Israel's largest healthcare provider said Sunday a study of more than half a million fully vaccinated Israelis indicated the Pfizer/BioNTech jab gave 94 percent protection against COVID-19.

Vaccination

AstraZeneca files vaccine for approval in Japan

AstraZeneca said Friday it has filed for approval of its coronavirus vaccine in Japan, becoming the second major pharmaceutical firm to ask Tokyo to authorise its jabs.

Vaccination

BioNTech-Pfizer pledges up to 75 mn more jabs to EU

BioNTech and Pfizer said Monday they will ramp up their coronavirus vaccine deliveries to the European Union, pledging to send up to 75 million extra doses to the bloc in the spring.

page 22 from 40